Roche appoints Mark Dawson as new Head of Pharma Research and Early Development
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
The company’s EBITDA margin remained resilient above 20%
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Subscribe To Our Newsletter & Stay Updated